Related Experiment Video

Updated: May 1, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.1K

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis

S Nakashima1, T Matsui1, M Takeuchi2

  • 1Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|April 9, 2014
PubMed

Insights

Linagliptin, a DPP-4 inhibitor, shows promise for diabetic nephropathy. It reduces kidney damage by inhibiting AGE-RAGE oxidative stress, independent of glucose-lowering effects.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Advanced glycation end products (AGEs) and their receptor (RAGE) are implicated in diabetic nephropathy.
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors, like linagliptin, may offer therapeutic benefits.
  • Previous studies show linagliptin suppresses AGE-induced oxidative stress and ICAM-1 expression in endothelial cells.

Purpose of the Study:

  • To investigate the glucose-lowering independent effects of linagliptin on experimental diabetic nephropathy.
  • To evaluate linagliptin's impact on renal damage markers in streptozotocin-induced diabetic rats.

Main Methods:

  • Diabetic rats were treated with linagliptin for 2 weeks.
  • Assessed serum DPP-4 levels, kidney AGEs, RAGE gene expression, oxidative stress markers (8-hydroxy-2'-deoxyguanosine), albuminuria, ICAM-1 mRNA, and lymphocyte infiltration.

Main Results:

  • Linagliptin treatment did not alter hyperglycemia but significantly reduced AGEs, RAGE expression, and oxidative stress in diabetic rat kidneys.
  • Linagliptin administration also decreased albuminuria, renal ICAM-1 mRNA levels, and glomerular lymphocyte infiltration.

Conclusions:

  • Linagliptin demonstrates beneficial effects on diabetic nephropathy by mitigating AGE-RAGE-mediated oxidative stress in the kidney.
  • DPP-4 inhibition via linagliptin presents a potential therapeutic strategy for managing diabetic nephropathy.

More Related Videos

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

8.1K
Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

4.5K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
59